In Brief: Genentech/Idec Idec-Y2B8
Executive Summary
Genentech/Idec Idec-Y2B8: Genentech returns marketing rights to Idec's radioimmunotherapy for relapsed or refractory non-Hodgkin's B-cell lymphoma. A pivotal trial design for Idec-Y2B8 is being discussed with FDA; Idec anticipates trial will begin in the first quarter of 1998...